UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 26, 2010

ACCESS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

	Delaware	0-9314	83-0221517
(St	tate or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
		2000	
		2600 Stemmons Freeway, Suite 176 Dallas, TX 75207	
	(Addr.	ess of principal executive offices) (Zip Co	de)
	(7700)	(Zip Co	
		(214) 905-5100	
	(Regist	rant's telephone number, including area c	ode)
		N/A	
	(Former na	me or former address, if changed since las	et renort)
	(Tormer na	ine of former address, if changed since has	n lopoit)
Che	ck the appropriate box below if the Form 8-K fil	ling is intended to simultaneously satisfy	he filing obligation of the registrant under any of
the	following provisions (see General Instruction A.	2. below):	
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
_	Written communications pursuant to Rule 423	under the Securities Net (17 C1 R 250.42	3)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
_			
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		
_	1 10-commencement communications pursuant	to Rule 130-4(c) under the Exchange Ac	(1/ C11(270.130-7(0))

Item 5.07. Submission of Matters to a Vote of Security Holders.

The annual meeting of stockholders of Access Pharmaceutical, Inc. (the "Company") was held on May 26, 2010. The following matters were acted upon:

1. ELECTION OF DIRECTORS

Mark J. Ahn, Ph.D and Mark J. Alvino were both elected to serve as directors of the Company until their successors are duly elected and qualified. The results of the election of directors are as follows:

 Nominee
 Votes For
 Votes Withheld

 Mark J. Ahn, Ph.D
 14,057,346
 581,269

 Mark J. Alvino
 13,864,613
 774,002

2. AMENDMENT OF THE COMPANY'S 2005 EQUITY INCENTIVE PLAN

A proposal to amend the Company's 2005 Equity Incentive Plan was approved by the following votes:

 Votes For
 Votes Against
 Abstain
 Broker Non-Votes

 13,520,119
 830,248
 288,247
 5,612,878

3. RATIFICATION OF APPOINTMENT OF WHITLEY PENN LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY.

Ratification of the appointment of Whitley Penn LLP as the independent registered public accounting firm of the Company was approved by the following votes:

 Votes For
 Votes Against
 Abstain
 Broker Non-Votes

 19,823,921
 130,454
 25,366
 0

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Access Pharmaceuticals, Inc. (Registrant)

By: /s/ Stephen B. Thompson
Stephen B. Thompson
Vice President and
Chief Financial Officer

Dated May 29, 2010